Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter

Journal of Immunology

Volumn 167, Issue 1, 2001, Pages 98-106

  Deffrennes, V ^a   Vedrenne, J ^a   Stolzenberg, M C ^a   Piskurich, J ^a   Barbieri, G ^a   Ting, J P ^a   Charron, D ^a   Alcaide Loridan C ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION;

EID: 0035400015     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.1.98     Document Type: Article

References (54)

1. Biological therapy of melanoma
2. Cancer tumor antigens
3. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
4. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
5. 2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides
6. CD4 T cells and their role in antitumor immune response
7. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes
8. + cytotoxic T cells in association with histocompatibility leukocyte antigen DR11
9. + cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles
10. + melanoma
11. Expression of Ia-like antigens on cultured human malignant melanoma cell lines
12. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens
13. Sequences and factors: A guide to MHC class II transcription
14. + T cell epitopes from NY-ESO-1 presented by HLA-DR molecules
15. HLA-DR antigen expression in primary melanomas of the skin
16. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma?
17. Pathology and prognostic factors
18. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
19. Immunochemical and functional analysis of HLA class II antigens induced by recombinant interferon on normal epidermal melanocytes
20. Major histocompatibility complex class II deficiency: Clinical manifestations, immunologic features, and outcome
21. Organ-specific autoimmunity: A (1986) overview
22. Class II MHC genes: A model gene regulatory system with great biologic consequences
23. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients
24. RFXAP, a novel subunit of the RFX DNA binding complex, is mutated in MHC class II deficiency
25. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome)
26. CREB regulates MHC class II expression in a CIITA-dependent manner
27. Monoclonal antibodies to NF-Y define its function in MHC class II and albumin gene transcription
28. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome)
29. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter
30. Regulation of MHC class II expression by interferon-γ mediated by the transactivator gene CIITA
31. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA
32. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA
33. Isolation of a B-cell-specific promoter for the human class II transactivator
34. Identification of distinct regions of 5′ flanking DNA that mediate constitutive, IFN-γ STAT1, and TGF-β-regulated expression of the class II transactivator gene
35. Activation of the MHC class II transactivator CIITA by interferon-γ requires cooperative interaction between Stat1 and USF-1
36. Two distinct γ interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor β
37. Monoclonal antibodies against HLA-DRw antigens
38. Detection of a novel human class II HLA antigen
39. Distribution of class II DQ antigens on normal and leukemic lymphoid cells
40. Regulation of cytomegalovirus gene expression: α and β promoters are transactivated by viral functions in permissive human fibroblasts
41. Defective MHC class II expression in an MHC class II deficiency patient is caused by a novel deletion of a splice donor site in the MHC class II transactivator gene
42. IL-1β inhibits IFN-γ-induced class II MHC expression by suppressing transcription of the class II transactivator gene
43. Spacing and orientation of bipartite DNA-binding motifs as potential functional determinants for POU domain factors
44. Transcriptional responses to polypeptide ligands: The JAK-STAT pathway
45. CIITA B-cell-specific promoter suppression in MHC class II-silenced cell hybrids
46. The Brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells
47. The POU domain transcription factor Brn-2: Elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression
48. The control of gene expression in melanocytes and melanomas
49. Quantitative control of MHC class II expression by the transactivator CIITA
50. Differential expression of MHC class II isotype chains
51. Polymorphism in the 5′ flanking region of the HLA-DQA1 gene and its relation to the DR-DQ phenotype
52. The class II transactivator prevents activation-induced cell death by inhibiting fas ligand gene expression
53. The RAG cell line defines a new complementation group of MHC class II deficiency
54. Evidence for retinoblastoma protein (RB) dependent and independent IFN-γ responses: RB coordinately rescues IFN-γ induction of MHC class II gene transcription in noninducible breast carcinoma cells